ATS View
한국어

RPbio KRX:314140KOSDAQ

알피바이오 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h2
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11

In Q2 2026, RPbio reported revenue of ₩39.8bn, up 11.4% year on year, and operating profit of ₩4.1bn. RPbio (알피바이오) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 2 articles.

RPbio quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩39.8bn+11.4%₩4.1bn₩3.0bn
Q1 2026₩35.1bn+3.3%₩2.4bn₩2.6bn
Q4 2025 derived₩33.3bn+6.4%₩684m₩863m
Q3 2025₩33.2bn+18.2%₩273m₩276m
Q2 2025₩35.7bn+11.3%₩2.3bn₩1.8bn
Q1 2025₩34.0bn+4.6%₩1.8bn₩1.7bn
Q4 2024 derived₩31.3bn-12.0%₩357m₩1.1bn
Q3 2024₩28.1bn-32.3%−₩1.3bn−₩1.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

RPbio top stories 2 weeks, by number of outlets

  1. 1
    [르포]“40년 노하우로 신제형 개발”…알피바이오, 해외 시장 정조준
    1 outlets · 2 articlesFirst report Sep 15 08:42 이데일리

Latest RPbio news Korean headlines